Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 15 of 40 results for ustekinumab

  1. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

  2. Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

  3. Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

    Evidence-based recommendations on ustekinumab (Stelara) for treating moderately to severely active ulcerative colitis in adults.

  4. Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

    Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.

  5. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

  6. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

  7. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

  8. Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

    Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years.

  9. Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

    Evidence-based recommendations on upadacitinib (Rinvoq) for previously treated moderately to severely active Crohn’s disease in adults.

  10. Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

    Evidence-based recommendations on mirikizumab (Omvoh) for treating moderately to severely active ulcerative colitis in adults.

  11. Guselkumab for treating moderate to severe plaque psoriasis (TA521)

    Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.

  12. Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

    Evidence-based recommendations on risankizumab (Skyrizi) for previously treated moderately to severely active Crohn's disease in people 16 years and over.

  13. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

  14. Risankizumab for treating moderate to severe plaque psoriasis (TA596)

    Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults.

  15. Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

    Evidence-based recommendations on ozanimod (Zeposia) for treating moderately to severely active ulcerative colitis in adults when conventional or biological treatments cannot be tolerated or are not working well enough.